Literature DB >> 10656311

The diagnosis and management of Acanthamoeba keratitis.

J P McCulley1, H Alizadeh, J Y Niederkorn.   

Abstract

PURPOSE: The purpose of this study was to evaluate the immunology, pathogenesis and therapy of Acanthamoeba keratitis.
METHODS: The recent development of an animal model of Acanthamoeba keratitis and its impact on the medical treatment and immunology of Acanthamoeba keratitis was reviewed.
RESULTS: After initial reports, Acanthamoeba infection of the cornea remained a rare disease until an association with contact lens wear was first recognized. Although the disease is closely associated with contact lens wear, it appeared that the contaminated solutions that were coming into contact with the lenses caused the disease. All types of contact lenses can be associated with development of Acanthamoeba keratitis. Therefore, the contact lens serves as a carrier of Acanthamoeba to the surface of the eye. The typical patient with Acanthamoeba keratitis is a young healthy individual who is either a contact lens wearer or has had significant exposure to water contaminated with Acanthamoeba. There are several risk factors such as corneal trauma, contaminated solution and contact lenses that have been reported to be associated with Acanthamoeba keratitis. In spite of significant improvement in the diagnosis of Acanthamoeba keratitis, progress in developing and utilizing effective antimicrobial agents for treating this disease have been disappointing. A growing body of evidence suggests that the mammalian immune system, if properly activated, is capable of preventing and controlling ocular infections.
CONCLUSIONS: In order to develop effective immunotherapeutic modalities, and to better understand the immune effector mechanisms that protect the cornea against Acanthamoeba infection, it is necessary to fully characterize and evaluate the immunobiology of Acanthamoeba keratitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656311

Source DB:  PubMed          Journal:  CLAO J        ISSN: 0733-8902


  9 in total

1.  Biochemical characterization and functional studies of Acanthamoeba mannose-binding protein.

Authors:  Marco Garate; Ibis Cubillos; Jeffrey Marchant; Noorjahan Panjwani
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Oral immunization with Acanthamoeba castellanii mannose-binding protein ameliorates amoebic keratitis.

Authors:  M Garate; H Alizadeh; S Neelam; J Y Niederkorn; N Panjwani
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

Review 3.  Neuroparasitic infections: cestodes, trematodes, and protozoans.

Authors:  M D Walker; J R Zunt
Journal:  Semin Neurol       Date:  2005-09       Impact factor: 3.420

4.  Morphological, physiological and molecular biological characterisation of isolates from first cases of Acanthamoeba keratitis in Slovakia.

Authors:  Viera Nagyová; Arpád Nagy; Jozef Timko
Journal:  Parasitol Res       Date:  2010-02-02       Impact factor: 2.289

5.  Modulation of corneal and stromal matrix metalloproteinase by the mannose-induced Acanthamoeba cytolytic protein.

Authors:  Hassan Alizadeh; Haochuan Li; Sudha Neelam; Jerry Y Niederkorn
Journal:  Exp Eye Res       Date:  2008-06-25       Impact factor: 3.467

6.  Amoebicidal activities of alexidine against 3 pathogenic strains of acanthamoeba.

Authors:  Hassan Alizadeh; Sudha Neelam; H Dwight Cavanagh
Journal:  Eye Contact Lens       Date:  2009-01       Impact factor: 2.018

7.  A case of medication-resistant acanthamoeba keratitis treated by corneal crosslinking in Turkey.

Authors:  Goktug Demirci; Akif Ozdamar
Journal:  Case Rep Ophthalmol Med       Date:  2013-12-22

8.  Diagnosis of infections caused by pathogenic free-living amoebae.

Authors:  Bruno da Rocha-Azevedo; Herbert B Tanowitz; Francine Marciano-Cabral
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-02

9.  Acanthamoeba keratitis: a 12-year experience covering a wide spectrum of presentations, diagnoses, and outcomes.

Authors:  Michael A Page; William D Mathers
Journal:  J Ophthalmol       Date:  2013-06-12       Impact factor: 1.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.